Panmure Liberum has increased its target price for Hikma Pharmaceuticals from 1,600p to 1,900p following the company's strong first-half results, which exceeded expectations. The broker noted that the positive interim results support further share price upside, contingent on Hikma meeting its full-year 2026 financial forecasts. While earnings forecasts were slightly raised, broader projections remain aligned with market consensus. The broker also highlighted the importance of Hikma's increased research and development investment translating into more predictable earnings to sustain the stock's rerating.
Mama's Creations reported a strong Q2 fiscal 2027 with revenue up 55% to $54.6 million and net income doubling to $2.6 million. The company’s growth is driven by new product launches, effective cross-selling, and inclusion in Costco's national mailer...
VinFast Auto Ltd. is set to release its Q3 2026 earnings with analysts expecting a loss per share of $0.33 and revenues around $1.15 billion. The Vietnamese electric vehicle maker is expanding internationally, promoting its VF 9 SUV in Canada and ben...
Tesla's stock dropped more than 7% following a disappointing Cybercab launch that lacked key details like pricing and order mechanisms. Analyst Gordon Johnson from GLJ Research reiterated a 'Sell' rating and set a 12-month price target near $24, impl...
Bitcoin surged past $82,000 before sharply falling below $78,700, erasing nearly all gains after strong US employment data reduced expectations for a Federal Reserve rate cut. This sudden reversal triggered over $295 million in long position liquidat...
Hargreaves Lansdown, the UK's largest investment platform, has started offering Bitcoin products to about 2 million clients. However, this launch comes five months after the UK government closed the tax-free window for holding Bitcoin in ISAs, which ...
